New York, New York-- (Newsfile Corp. - February 23, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against ICON plc (NASDAQ: ICLR) and certain ...

Inorganic growth refers to the expansion of a business through external activities such as mergers and acquisitions (M&A). This article explores the concept of inorganic growth, highlighting its ...

India is increasingly making a mark in the global pharmaceutical Contract Development and Manufacturing Organization (CDMO) sector while rapidly scaling up its production in fine chemicals, ...

Innoviva's shift to specialty therapeutics is backed by strong financials and a robust pipeline. Read why INVA stock presents ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

CARTERVILLE, Mo. — A new business means the beginning of a new opportunity for Carterville. Rachel Maddow breaks down new ...

Pope Francis was in critical condition Saturday after he suffered a prolonged asthmatic respiratory crisis while being ...

Swiss Scientists Pioneer an Innovative CO₂ Conversion Process Turning Carbon Dioxide into a Valuable Industrial Chemical A ...

John Arena, interim president of global pharma services at Cencora, discusses the importance of engaging with partners as ...

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...

Icon's balance sheet is sound, with its revenue cyclicality and operating leverage each possessing a medium rating. Icon has historically maintained a fairly conservative balance sheet, and it ended ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against ...